Who
Shawn Tomasello
Director
Company insider
Files Form 4 as: Director, 4D Molecular Therapeutics; Director, Cabaletta Bio; Director, Kalaris Therapeutics; Director, Gamida Cell; Director, Tcr2 Therapeutics; Director, UroGen Pharma; Director, Principia Biopharma; Director, Abeona Therapeutics.
In numbers
- Trades disclosed
- 85
- Buys
- 2
- Sells
- 5
- Bought
- $116K
- Sold
- $1.1M
- Companies
- 11
- Companies where not an officer
- 9
- First trade
- 18 Aug 2014
- Last trade
- 17 Jun 2026
- Last filed
- 18 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 17 Jun 2026filed 18 Jun 2026 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 9 Jun 2026filed 10 Jun 2026 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 21 Jan 2026filed 21 Jan 2026 | CABA Cabaletta BioBiotechnology | SEC FORM 4 Bought | $50K22,725 at $2.21 | filing |
| 21 Jan 2026filed 21 Jan 2026 | CABA Cabaletta BioBiotechnology | SEC FORM 4 Bought | $50K22,725 at $2.21 | filing |
| 17 Jun 2025filed 20 Jun 2025 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 9 Jun 2025filed 9 Jun 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —44,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code D | —22,000 at $0.00 | filing |
| 19 May 2025filed 19 May 2025 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | KLRS Kalaris TherapeuticsBiotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2024filed 4 Jun 2024 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —22,000 at $0.00 | filing |
| 21 May 2024filed 23 May 2024 | FDMT 4D Molecular Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 31 Jan 2024filed 2 Feb 2024 | Gamida Cell | SEC FORM 4 Code A | —200,000 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —56,600 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Cell | SEC FORM 4 Code A | —28,300 at $0.00 | filing |
| 19 Oct 2023filed 20 Oct 2023 | Gamida Celloption or derivative | SEC FORM 4 Code A | —17,000 at $0.00 | filing |
| 21 Jul 2023filed 24 Jul 2023 | CABA Cabaletta Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —44,000 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
Related people
Nobody else traded the same names lately.